In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Austrianova FSG Biotechnologie GMBH

Executive Summary

Austrianova is pursuing both cell- and retroviral gene-therapy technologies to treat cancer. The Vienna-based company's most advanced project is a cell-therapy designed to treat pancreatic cancer which has gained Orphan Drug status in Europe.

You may also be interested in...



Vical Leaves Gene Therapy for Vaccines

Is gene therapy ever going to become a routine, reliable method of disease treatment? It appears that the odds of success in anything like the near term are slimming. Now one of the first companies to get involved in gene therapy is finally giving up on it: San Diego-based Vical Inc., founded in 1987, recently announced its intention to use its naked DNA technology to develop a vaccine for cytomegalovirus (CMV).

Gene Delivery: Looking Past the Skeptics

The criticism of gene therapy has been continual and consistent. But in fact, at least some delivery systems do work. It is true, however, that not all vectors work in all diseases, and the challenge for gene delivery start-ups is figuring out which ones work where.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004871

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel